To probe the effect of STING activation only in tumor cells, we introduced mutations in the antibody Fc region that abrogate FcγR interactions while retaining tumor cell (antigen) binding as well as FcRn binding32 (Fig. 1c). The gene discussed is STING1; the disease is neoplasm.